Product Details for ANDA 206318
RIVASTIGMINE (RIVASTIGMINE)
4.6MG/24HR
Marketing Status: Prescription
9.5MG/24HR
Marketing Status: Prescription
13.3MG/24HR
Marketing Status: Prescription
4.6MG/24HR
Marketing Status: Prescription
Active Ingredient: RIVASTIGMINE
Proprietary Name: RIVASTIGMINE
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 4.6MG/24HR
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A206318
Product Number: 001
Approval Date: Mar 4, 2019
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Prescription
Patent and Exclusivity Information
RIVASTIGMINE (RIVASTIGMINE)
Proprietary Name: RIVASTIGMINE
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 4.6MG/24HR
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A206318
Product Number: 001
Approval Date: Mar 4, 2019
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Prescription
Patent and Exclusivity Information
9.5MG/24HR
Marketing Status: Prescription
Active Ingredient: RIVASTIGMINE
Proprietary Name: RIVASTIGMINE
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 9.5MG/24HR
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A206318
Product Number: 002
Approval Date: Mar 4, 2019
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Prescription
Patent and Exclusivity Information
RIVASTIGMINE (RIVASTIGMINE)
Proprietary Name: RIVASTIGMINE
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 9.5MG/24HR
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A206318
Product Number: 002
Approval Date: Mar 4, 2019
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Prescription
Patent and Exclusivity Information
13.3MG/24HR
Marketing Status: Prescription
Active Ingredient: RIVASTIGMINE
Proprietary Name: RIVASTIGMINE
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 13.3MG/24HR
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A206318
Product Number: 003
Approval Date: Mar 4, 2019
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: RIVASTIGMINE
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 13.3MG/24HR
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A206318
Product Number: 003
Approval Date: Mar 4, 2019
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Prescription
Patent and Exclusivity Information